In the assessment of severity in coronavirus disease 2019 (COVID-19), the modified Brit\_x0002\_ish Thoracic Society (mBTS),CURB65 et al. rules identifies patients with severe pneumonia but not patients who might be suitable for home management. A multicentre prospective study was conducted to derive and validate a practical severity assessment model for stratifying adults hospitalised with COVID-19 into different management groups.
1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 30-day evaluation period: 4. Completion of baseline procedures Participants were assessed for 30 days and completed all safety monitoring.
Study Type
OBSERVATIONAL
Enrollment
3,000
Likely suitable for home treatment
Consider hospital supervised treatment
Manage in hospital as severe pneumonia
The 900th Hospital of the Joint Logistic Support Force, PLA
Fuzhou, Fujian, China
RECRUITINGMortality
Mortality within 30days after diagnosis; Death from any cause
Time frame: 30days
Deterioration of the condition
Deterioration of the condition: refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 9) The development from asymptomatic to mild/general-type. The development from mild to general-type/severe type The development from general-type to severe/critical type The development from severe to critical type
Time frame: Day 1 to 30 days
Time to sustained disappearance of clinical symptoms
Time to sustained disappearance of clinical symptoms
Time frame: Up to 30 days
Percentage of participants with no clinical symptom
Percentage of participants with no clinical symptoms from baseline to Day 3, 5, 7, 10, 14, 21 and 28
Time frame: Day 3, 5, 7, 10, 14, 21 and 28
Percentage of participants who turned negative for SARS-CoV-2 and/or COVID-19 antigen
Percentage of participants who turned negative for SARS-COV-2 COVID-19 antigen at Day 3, 5, 7, 10, 14, 28
Time frame: Day 3, 5, 7, 10, 14, 28
Safety assessment Results: such as AEs and SAEs through Day 30
Safety assessment Results: such as AEs and SAEs through Day 30
Time frame: Up to 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.